Rising incidence of musculoskeletal disorders represents key global public health challenges. Leveraging extensive pre clinical expertise in musculoskeletal drug development, JOINN offers diverse musculoskeletal disease models covering neuromuscular impairment, bone lesions and joint injury, supporting pharmacodynamic evaluation of small molecule drugs, antibodies, vaccines and nucleic acid therapeutics.
| Model | Endpoints | Species |
| Botulinum Toxin Efficacy Test | LD50 / DAS scoring / CMAP (Compound Muscle Action Potential) | Rats / Mice |
